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Abstract
The accepted use of left ventricular assist device (LVAD) technology as a good alternative for the treatment of patients with
advanced heart failure together with the improved survival of the LVAD-supported patients on the device and the scarcity of
donor hearts has significantly increased the population of LVAD-supported patients. The expected and non-expected
device-related and patient–device interaction complications impose a significant burden on the medical system exceeding
the capacity of the LVAD implanting centres. The ageing of the LVAD-supported patients, mainly those supported with the
‘destination therapy’ indication, increases the risk for those patients to experience comorbidities common in the older
population. The probability of an LVAD-supported patient presenting with medical emergency to a local emergency
department, internal, or surgical ward of a non-LVAD implanting centre is increasing. The purpose of this trilogy is to supply
the immediate tools needed by the non-LVAD specialized physician: ambulance clinicians, emergency ward physicians, general
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cardiologists, internists, anaesthesiologists, and surgeons, to comply with the medical needs of this fast-growing population of
LVAD-supported patients. The different issues discussed will follow the patient’s pathway from the ambulance to the
emergency department and from the emergency department to the internal or surgical wards and eventually to the discharge
home from the hospital back to the general practitioner. In this first part of the trilogy on the management of LVAD-supported
patients for the non-LVAD specialist healthcare provider, after the introduction on the assist devices technology in general,
definitions and structured approach to the assessment of the LVAD-supported patient in the ambulance and emergency
department is presented including cardiopulmonary resuscitation for LVAD-supported patients.
Keywords LVAD; General description; Emergency medical systems; CPR
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Introduction
The prevalence of patients with advanced heart failure (HF) is
increasing with the growing number of total HF patients,
comprising an estimated number of 1–10% of the overall HF
population.1,2 The gold standard for treatment of these pa-
tients is heart transplantation (HTx), but this option is limited
by several factors, mainly due to the restricted supply of do-
nor organs, but also by the presence of contraindications to
HTx, such as elevated pulmonary vascular resistance or re-
cent malignancy.3 During the past two decades, as a conse-
quence of the donor organ’s shortage, the mechanical
circulatory support (MCS) and primarily, the left ventricular
assist devices (LVADs) have become one of the most impor-
tant tools for the treatment of advanced HF patients. This
shortage of organs for donation is not expected to improve,
and thus, an increase in the number of LVAD-supported pa-
tients is foreseen.
There are three major indications for MCS in end stage HF
patients:
i Bridge to transplantation (BTT) or to candidacy
ii Destination therapy (DT)
iii Bridge to recovery.
The BTT and DT indication includes advanced HF patients
who need the LVAD support due to very poor prognosis
and reduced quality of life as an immediate life sustaining
measure. Included in the BTT and bridge to candidacy group
are advanced HF patients on the waiting list for HTx and
those with relative contra-indications to HTx, which are ex-
pected to improve on the LVAD support, such as cardiac ca-
chexia, high pulmonary vascular resistance, or those with
recently treated malignancy whereby bridging with the LVAD
support the time needed to reduce the recurrence rate of the
malignancy post HTx.4 Included in the DT group are advanced
HF patients who are not expected to undergo HTx due to con-
traindications that are not likely to change during LVAD sup-
port, such as advanced age.
The bridge to recovery group consists of deteriorating ad-
vanced HF patients with potentially reversible aetiologies
such as viral myocarditis or per-partum cardiomyopathy.
The survival of the patients with advanced HF who are sup-
ported with the new generations of LVADs is constantly im-
proving reaching 86.6% and 82.3% 1 and 2 year survival
rates with the HeartMate3 (HM 3) LVAD,2,4 very similar to
the survival post HTx. The shortage of donor organs and im-
proved quality of the modern LVADs practically implies that
many of patients with advanced HF will be getting the de-
vices as DT.5 The total number of LVAD-supported patients
and in particular those implanted as DT is expected to in-
crease significantly. The regained independence of the pa-
tient who is supported with the LVAD results in extended
periods when the patient is alone, without the surveillance
of his close caregiver. Consequently, it will become more
common for the LVAD-supported patient to be found in an
emergent medical situation where there is no close caregiver
to rely on by the emergency medical suppliers.
Furthermore, the improved survival on LVAD support re-
sults in longer support times, with patients ageing on the
MCS, facing an extended risk for device-related complications
as well as for the occurrence of the variety of chronic dis-
eases and comorbidities prevalent in the ageing population.
These patients may be in the need for different medications
and may require non-cardiac surgeries. The growing popula-
tion of LVAD-supported patients will pose a challenge to all
the medical community starting from their family physicians,
nurses, the emergency medical services (EMS) teams through
the emergency department (ED), the internal and surgical
wards and to the anaesthesiologists in the operating rooms,
the cardiologists in the clinics, and in the general or cardiac
intensive care units, the LVAD coordinators and the LVAD
specialists.
The aims of this paper are to introduce the
LVAD-supported patients and the common medical issues
they encounter to the multidisciplinary non-LVAD specialist
physicians; to suggest when and how to approach, evaluate,
manage, and treat those patients; to supply the immediate
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tools needed; and to comply with the medical needs of this
fast-growing population of being an LVAD-supported patient.
The different issues discussed will follow the patient’s path
from the ambulance to the ED, from the ED to the internal or
surgical wards, and eventually to his discharge home and to
the general practitioner.
Left ventricular assist device description
Until June 2021, the most used LVADs were HeartWare™
(HW™), HeartMate II™ (HM II™), and HeartMate3™ (HM 3™).
The three are all continuous flow devices: the HW™ and
HM 3™ produce centrifugal flow and the HM II™ axial flow. Re-
cently, the manufacturer of HeartWare has announced stop-
ping its production. In the schematic LVAD system shown in
Figure 1, the inflow cannula connects the LV cavity to the
pump (the body of the LVAD) and transfers the blood from
the LV cavity to the pump. The pump is connected to the as-
cending aorta via the outflow graft through which it pumps
the blood to the ascending aorta thus by-passing the failing
left ventricle. The pump in also connect by the driveline
(DL), a cable that exits the body at the lower abdominal wall,
to the external controller and the energy supply. The DL con-
tains two sets of three wires: two for the transfer of power to
the device and one for transferring data to the controller and
a spare set of wires. The controller is the system’s computer
and is connected to the DL in one side and to two power
sources on the other: the batteries. The controller can also
be connected to a wall socket as an external power source.
Left ventricular assist device parameters
Understanding of the device function and knowledge of its
basic parameters are essential to ensure the appropriate
management and care of LVAD patients. The following defini-
tions of the displayed LVAD parameters are important to the
understanding of how mechanical circulatory support devices
operate. The typical operating parameters of the 3 most used
LVADs is presented in Table 1.
Pump speed
Pump speed is displayed by the revolutions per minute and
determine the pump flow. This pump speed is set for each
device by the LVAD team and may be modified as needed ac-
cording to changes in the patient’s clinical parameters. Opti-
mization of the pump speed can be performed using a
ramped speed study: increasing and decreasing the pump
speed with concomitant monitoring of haemodynamic and/
or echocardiographic parameters to determine the optimal
speed.
Pump power
The LVAD pump power is a measure of the current and volt-
age applied to the motor and varies directly with pump speed
and flow. Pump power is displayed in Watts.
Pump flow
The amount of blood flowing through the pump and reported
on the system controller, displayed in litres per minute. Nota-
bly, the flow is an estimated value based on pump speed and
the power needed to exert that speed. The device flow is di-
rectly proportional to the rotor speed and inversely related to
the difference of pressure in the inflow and outflow cannulas.
The flow estimation may not be accurate in the cases of phys-
iologic derangements such as aortic insufficiency or LVAD
dysfunction, including pump thrombosis.
Figure 1 Schematic illustration of an left ventricular assist device (LVAD)
with its components.
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Pulsatility index
The pulsatility index (PI) corresponds to the magnitude of
flow pulse through the pump and is determined by pump
speed and the patient’s native heart function. The controller
measures temporal power fluctuations to give an estimate
of pulsatility through the pump in numbers for the
HeartMate devices and represented graphically as a wave-
form for the HeartWare™ device. The magnitude of the PI
value is related to the amount of assistance provided by
the pump: higher values indicate more ventricular filling
and higher left ventricular pulsatility while lower values indi-
cate less ventricular filling and lower pulsatility. The PI fluc-
tuates with changes in the volume status and in the
heart’s contractility. It increases when LV preload and con-
tractility increase, and it decreases when blood volume
and LV afterload are reduced and when there is an obstruc-
tion to the inflow cannula or to the outflow graft that
causes low flow and abnormal power. PI values should be
routinely monitored and should not vary significantly during
resting conditions.
It is important to remember that one single pump
parameter is not a surrogate for monitoring the overall
clinical status of the patient and any change in parameters
should be evaluated with all clinical considerations in mind.
Management of left ventricular assist
device-supported patients by the ‘first
to contact’ in the ambulance and/or
emergency department
Despite the technological advances and improved survival,
device-related complications, and patient-device interaction,
impose a significant burden on the medical system exceeding
the capacity of the LVAD implanting centres. The probability
a patient who is supported by an LVAD will present with med-
ical emergency to either his general practitioner, the local
EMS team, the emergency department (ED), or to the medi-
cal wards (internal or surgical) in a non-LVAD implanting cen-
tre close to their home is increasing.
The EMS clinician, ED physician, general cardiologist, and
internist are all expected to be familiar with the emergencies
and other medical needs an LVAD-supported patient may
face.
The LVAD implanting centres are encouraged to train
healthcare providers, including general practitioners and
members of the EMS team, who might be called upon in
an emergent setting. The EMS team should learn how to
manage the LVAD patent in the acute scenario and should
have the appropriate equipment available. The EMS team
should learn how to guide bystanders during rescue
attempts.
Initial assessment of the left ventricular assist
device-supported patient in the ambulance and/
or emergency department
Despite the impressive improvement in survival, LVAD-
supported patients yet retain significant morbidity. Up to
60% of the patients recorded in the Interagency Registry
for Mechanically Assisted Circulatory Support (INTERMACS)
database have significant adverse events within the first
6 months of support and 60% need re-hospitalization within
this time period. The increasing number of LVAD-supported
patients and their retained morbidity calls for better under-
standing of LVAD-related care within broader circles of
healthcare providers. These include distinguishing the
unique clinical characteristics, reasons for seeking unplanned
medical care, and the initial evaluation scheme of the
LVAD-supported patients.
The LVAD-supported patients are dependent on the appro-
priate function of the LVAD: acute malfunction or a simple
lack of electrical energy may necessitate urgent assistance.
The LVAD maintains its function by electrical supply utilizing
rechargeable batteries (lasting between 6 and 19 h) or by
the external electrical system. The energy supply is connected
to the LVAD motor via a controlling element (controller) and
a cable (driveline). (Figure 1). Malfunctioning of this system
may trigger specific alarms and necessitate an appropriate re-
sponse. A few LVAD systems are currently used, and each has
its own specific characteristics. The three systems mostly
used in Europe and the USA are the HeartWare™ (HW™) also
named HVAD™ (Medtronic), the HeartMate II™, and the
HeartMate 3™ (Abbott). These three devices maintain a con-
stant flow from the left ventricle to the aorta leading to a
non-pulsatile physiology. Figure 2 shows three X-ray images
of the three devices. Because pulse pressure under usual cir-
cumstances of LVAD support is very small, the patients usu-
ally do not have a palpable pulse. Therefore, blood pressure
and oxygen saturation are unattainable in approximately
50% of patients using standard automatic cuffs and pulse
oximeters. On physical examination, a distinct humming of
the LVAD may be heard over the precordium. The driveline
exit site may be seen (preferably dressed and secured) at
the abdominal wall.
Despite the LVAD support, patients may maintain some of
the clinical characteristics of HF including fatigue and weak-
ness, volume overload, cachexia, and other comorbidities.
Furthermore, these patients are usually treated with multiple
medications targeting hypertension, diabetes, and dysli-
pidaemia as well as anticoagulation and anti-platelets. Fur-
thermore, LVAD patients have some typical and common
complications leading to medical attention. These include
thromboembolic complications (stroke and LVAD thrombosis),
bleeding tendency (minor, major, gastrointestinal, or surgical),
infections (with the driveline exit site a constant concern), aor-
tic incompetence, arrhythmias, and worsening HF.
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Any of the medical issues listed above may cause the
LVAD-supported patient to seek urgent or unplanned
medical attention. Most LVAD-supported patients are in
direct contact with the LVAD coordinator who will
respond to the majority of logistic and non-urgent issues.
Therefore, many patient’s visits to the ER will lead to
hospitalization. The reasons for referral are diverse and
include both specific and nonspecific LVAD-related issues.
The reported frequency of LVAD-related complaints
seems to differ between centres6,7 and change according
to the time post implant.8–10 Hospitalizations of LVAD
patients form a distinct array of device-related and
patient-related complaints justifying specialized education
and training.
During the initial evaluation, it is advised to consult with
the LVAD coordinator and close caregiver. In the absence or
difficulty of acquiring the blood pressure and peripheral
pulse, the stability of the patient should be assessed based
on alertness and obtainable signs of shock (such as short-
ness of breath, cold clammy skin, perspiration, and capillary
refill). An unstable patient should undergo rapid evaluation
for the adequate function of the LVAD system. An electro-
cardiogram (ECG) and bedside echocardiography may be
helpful in diagnosing arrhythmia and causes of haemody-
namic instability. Cardiopulmonary resuscitation (CPR) must
be started according to the protocol elaborated in this doc-
ument. A stable patient should be evaluated routinely with
focus on history and vital signs (using the Doppler tech-
nique to evaluate mean arterial pressure). The thorough
physical examination should include auscultation to the
LVAD precordial hum and the visible LVAD system: the bat-
teries, controller, and driveline. Alteration in mental status
needs to be rapidly evaluated with low threshold for brain
computed tomography (CT). An ECG is useful to diagnose
arrhythmias and a chest X ray should be performed to eval-
uate pulmonary conditions and the LVAD position.
Figure 2 X-ray images of the most used left ventricular assist devices (LVADs).
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Echocardiography is a useful tool to assess the volume sta-
tus, right ventricular function aortic incompetence, and ad-
equate LVAD function. Noteworthy, the constant cardiac
output generated by the LVAD may alter expected clinical
responses to acute cardiac and non-cardiac events:
LVAD-supported patients may remain non-symptomatic or
only mildly symptomatic despite undergoing ventricular
tachycardia (VT) or ventricular fibrillation (VF), event of
otherwise life-threatening outcome.
Medical history and sources of information
The anamnesis of an LVAD-supported patient should start
with determining the following:
i Manufacturer and model of the device.
ii Date of device implantation.
iii LVAD implanting centre.
iv Emergency contact phone number (24/7).
Some centres provide an ‘identity document’ bracelet that
includes all this data. In others, a quick response (QR) code
might also exist on the bracelet, and scanning it would bring
up more data on the patient’s specific device, alarms, and
troubleshooting.
The next stage should include asking the patient or his
close caregiver for any recent alarms. In most of the modern
devices today, an alarm is usually accompanied by a text mes-
sage explaining the possible problem and advises on how to
manage it. Following these LVAD-specific information, the
more clinical-oriented, continuous flow-related issues, should
be addressed: has there been any bleeding event that can be
related to the patient’s complaints and symptoms or a signif-
icant driveline infection suggesting that the patient might be
having an acute infection or be in septic condition? In those
patients implanted with an implantable cardioverter defibril-
lator (ICD) or cardiac re-synchronization therapy with a defi-
brillator, have there been any discharges from the
defibrillator implying that the symptoms are caused by a
tachyarrhythmia?
Some centres supply the LVAD-implanted patients with
an emergency card: ask the caregiver, or the patient if
responsive, to the presence of such a document: usually,
a simple one-page card describing the different device
alarms and how to troubleshoot them. Patients are
instructed to keep this emergency card in a visible and
easily accessed place. All the LVAD accessories, batteries
as well as their recharging docking and the controllers,
should also be examined for major malfunction and carried
with the patient in the need for transportation. For
troubleshooting the device, ask first the caregiver or the
patient himself for help as in most cases, they will probably
know how to respond, explain the significance of the
alarms, and may be of help by knowing the basic patient’s
parameters of the device.
Flow adequacy and patient stability
Most of the automated blood pressure (BP) devices and pulse
oximeters will be effective in measuring BP in approximately
50% of the LVAD-supported patients11; therefore, it is ad-
vised to apply this simple approach first. If the automated
BP device fails, then use the Doppler to measure mean arte-
rial BP (MAP): First, the Doppler transducer is placed on ei-
ther the brachial or radial artery and the arterial flow
detected in the resting condition. The manual cuff (sphygmo-
manometer) is then inflated and deflated slowly. The BP re-
corded when an arterial flow sound is heard is
approximately the MAP.
A MAP value of less than 50 mmHg indicates an unstable
patient, because the normal MAP range for LVAD-supported
patients is 60–80 mmHg. One of the most important and sim-
ple signs in the physical examination of the LVAD-supported
patient for evaluating the flow adequacy is assessing the pa-
tient’s capillary refill. A capillary refill of more than 2 s indi-
cates pathologic low BP. Cool and abnormal skin colour also
indicate inadequate flow.12 Evaluate the patient’s respiratory
status—is the patient breathing normally or has agonal
breathing or even apnoea.
Another good option for evaluating the flow adequacy of
an LVAD patient is the Capnograph. Since 2015, the
American Heart Association (AHA) EMS recommends
evaluating the correct placement of the advanced airway
and the efficacy of the chest compressions, with the
capnograph. It is therefore expected that all EMS teams
are equipped with this equipment, making it the most
important tool in evaluating the LVAD patient. Pulmonary
end-tidal CO2 (PETCO2) > 20 suggests that the patient has
adequate ventilation and BP13 with the restriction that for
patients without advanced airway support the value could
be inaccurate. Furthermore, similar to the pulse oximeter,
the capnograph is not a reliable tool for all
LVAD-supported patients, but if it does supply a reading in
the normal range, that can be trusted. Auscultating to the
patient’s chest can help diagnose lung congestion but most
importantly also allow assessing the hum produced by the
functioning LVAD. The LVAD hum is loud and easily heard:
It can be monotonic with the HarteMate II and
pseudo-pulsatile with HeartMate 3 representing the artificial
pulse that occurs every 2 s. The hum of the HeartWare is
monotonic unless the Lavare (‘washing’) cycle is activated,
in which case, every minute, a pulsatile tone is heard
reflecting abrupt speed decrease followed by speed
increase: decrescendo/crescendo tone. Importantly,
irrespective of the device, if no hum is heard, the LVAD is
not functioning.
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Common acute medical scenarios in
the LVAD-supported patient
Pump failure
The most common cause of pump failure is disconnection
from the power supply or a driveline fault. The patient should
be examined from the driveline exit site through the control-
ler and batteries to the wall socket. In case a problem is
found in the power supply, the issue of re-connecting the de-
vice to the power supply will be raised.
Low flow alarms
The flow signal in the controller is a calculated value that al-
though presented in units of litre per minute is based on cal-
culation of parameters derived from the speed and power
consumption of the device: In the contemporary LVADs, the
flow is not measured directly. Therefore, low flow alarm does
not necessarily mean that the patient has low cardiac output.
Common causes of a low flow alarm can be acute right-sided
HF, pulmonary embolism, or dehydration. In the case of low
flow alarm, it is advised to lay the patient down in the
Trendelenburg position with his legs lifted. In case this simple
manoeuvre silences the low flow alarm, dehydration as the
cause of the alarm is probably the reason. After a brief hae-
modynamic assessment, if the patient is not with overt vol-
ume overload, fluid resuscitation with a bolus of 500 cc
saline can be a good diagnostic and therapeutic option.
Pump thrombosis
Pump thrombosis can also present as an acute event the
LVAD-supported patient. The thrombosis can be in the pump
itself but also in the inflow or outflow cannulas. Pump throm-
bosis can be difficult to diagnose in the community setting,
but if after consulting the LVAD centre this complication is
raised, immediately transferring the patient to the nearest
LVAD centre is vital.
Stroke
Haemorrhagic or thrombotic stroke have been reported in
about 7% of the LVAD-supported patients per year.14 Stroke
in an LVAD-supported patient may be hard to diagnose as un-
responsiveness with no pulse can be wrongly interpreted as
absence of signs of life. In such a case, evaluate the patient’s
haemodynamics, first by physical examination: capillary refill
and the capnograph. In the case of suspected stroke, the
LVAD centre needs to be consulted regarding the most bene-
ficial next step: either immediately treat the patient in the
closest stroke unit, or if time permits, transfer the patient
to the LVAD centre.
Ventricular tachyarrhythmias: ventricular
fibrillation/ventricular tachycardia
The VF/VT will occur in approximately 50% of LVAD
patients.15 VF reduces the effective device flow by 32%.16
Some of the common aetiologies for VF/VT in LVAD patients
are myocardial scar post previous myocardial infarction, HF
exacerbation, suction event (suction mostly of the interven-
tricular septum by the LVAD inflow cannula), dehydration,
and electrolyte imbalance.17 During a VT/VF episode, the
LVAD patient can be clinically unstable, although, more often,
will be mildly symptomatic (complains may include shortness
of breath, weakness, or lightheadedness) or even completely
asymptomatic. In the event of a VT/VF caused by a suction
event due to dehydration, the VF/VT can be sustained until
the patient receives fluid resuscitation. Diagnosing this se-
quence of events might not be feasible by the EMS team.
The unstable LVAD patient with VT/VF needs to be treated
promptly as indicated for the non-LVAD patient with defibril-
lation and medications. Management of the haemodynami-
cally stable LVAD patient with VT/VF is challenging: if the
event is short, measured in minutes, immediate cardioversion
may prevent thrombus formation in the RV and/or on the
aortic valve. If the event is prolonged, thrombus formed in
those two locations cannot be ruled out. The patient should
be immediately transferred to a VAD centre for further eval-
uation and management.18
Bleeding
Bleeding, mainly from the gastrointestinal tract or nasophar-
ynx, can occur in up to 22% of the LVAD patients.14 In the
case of acute major blood loss in the community,
LVAD-supported patients should be treated as non-LVAD pa-
tients to reach MAP of 60–80 mmHg if BP can be measured,
to reach capillary refill of less than two seconds or normal
PETCO2 value.
Driveline infection
The driveline is the very source of infections at the port of en-
try of the driveline cable through the abdominal wall. The pa-
tient and caregiver should be enquired regarding recent
driveline infections. Evaluating and taking a swab from the
driveline exit site must be part of the routine physical exam-
ination of the LVAD-supported patients.
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The incidence of any infection in LVAD patients while on the
mechanical support is as high as 37%.19 The characteristics of
the continuous flow LVAD, being afterload dependent, can
result in increased cardiac output as a result of systemic arte-
rial vasodilatation caused by the septic event. Furthermore,
the deleterious effects on the myocardium caused by the cat-
abolic and inflammatory state of the septic event do not af-
fect the function of the LVAD resulting in a potential delay
in the occurrence of the common symptoms of an infection,
even of the state of septic shock. The management of this
acute scenario is just as for the non-LVAD patients.
In the presence of acutely alteredmental status, after ruling
out the above LVAD-related causes, investigate other aetiol-
ogies such as hypoglycaemia, drug overdose, and hypoxia.
In summary, LVADs are implanted more frequently in pa-
tients with advanced HF and significantly prolong their sur-
vival. However, the LVAD-supported patients retain
significant morbidity necessitating unplanned medical atten-
tion. The LVAD-supported patients have some unique
distinguishing features and LVAD-related complaints that ne-
cessitate specific education and training of the attending
medical staff. This document is intended to fill this gap in
knowledge and supply useful information for all medical care
suppliers not experts in the field of MCS who might need to
take care of LVAD patients.
• Educate and train the medical staff for the medical emer-
gencies unique to the LVAD patient.
• Most of the LVAD patients do not have a palpable pulse so
measuring BP and oxygen saturation may be difficult.
• Use clinical evaluation to assess the patient’s stability.
• In cases of device malfunction consult the patient or care-
giver and contact the LVAD centre.
Cardiopulmonary resuscitation for left
ventricular assist device-supported
patients
Although some of the causes for haemodynamic collapse of
an LVAD-supported patient are like those of the non-LVAD-
supported patients, others are device related and may pose
a complex diagnostic challenge.
The first to contact the patient should look for the signs of
life. Absence of signs of life is determined when the patient is
apnoeic (not breathing at all) or in agonal breathing, unre-
sponsive, and pale.
If the patient is known as an LVAD-supported patient, in-
spect the cables, controller, and batteries. Expose the
abdomen of the patient and look for the integrity of the
driveline exiting the abdominal wall.
Concomitantly, try to contact the LVAD centre, but do not
delay emergency treatment. In the absence of signs of life,
the first to have contacted the patient is encouraged to im-
mediately start CPR.
Chest compression
Chest compressions for LVAD patients although intuitive
raises certain issues that need to be addressed: Might chest
compressions cause pump dislodgement, tamponade, or in-
trathoracic bleeding? And also, is chest compression indeed
useful and if so, should it be performed manually or also
mechanically?
In a retrospective case study from a single centre20 com-
paring CPR in nine LVAD and non-LVAD patients, a delay
was found in starting in-hospital CPR in the LVAD patients. Al-
though in that study all nine patients included died, there
were no device dislodgement, dislocation, or bleeding issues
related to the chest compression. In another study,21 CPR was
successful in 50% of the eight LVAD patients described. The
survivors had no major neurologic deficit and no device dis-
lodgement, dislocation, or bleeding issues related to the
chest compression.
In the total of 25 LVAD patients who underwent chest
compression described in the literature, no dislocation, dis-
lodgement, bleeding, or tamponade have been reported.20–22
Due to the scarcity of the data and the emergent nature of
those events, a controlled study with data regarding the util-
ity of CPR in LVAD-supported patients is not expected. From
the existing case reports, it can be assumed that CPR with
chest compression in VAD patients is safe and might even
be helpful.
There are no data regarding mechanical chest compression
in LVAD patients but being much more aggressive then man-
ual can be harmful.
Left ventricular assist device reconnection
When the LVAD is disconnected from its power supply, it will
take approximately 20 min until it shuts off for the HM II and
HM 3™ although the HW™ will shut off immediately if the con-
troller is disconnected from its energy supply. Although
anticoagulated, the combination of stasis and artificial mate-
rial may result in thrombus formation in the system: in the
pump itself, and/or in the inflow or outflow cannulas. In con-
sidering reconnecting a non-operating LVAD, three important
issues should be taken into account:
i What is the patient’s condition
ii How long has the LVAD been disconnected?
iii Is it in or out of hospital resuscitation?
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The first thing that can help in the decision-making process
on whether to reconnect or not the disconnected LVAD is the
patient’s haemodynamic condition: Is the patient haemody-
namically stable or not? The reasoning for reconnecting an
unstable patient, for the sake of general organ perfusion, par-
ticularly the brain, does not apply for the stable
LVAD-supported patient. As long as the patient with a discon-
nected LVAD remains stable, it is advised to transfer the pa-
tient with the disconnected device to the nearest LVAD
centre where, based on a quick evaluation including deter-
mining how long has the device been disconnected, assess-
ment of the anticoagulation state of the patient, the device
model, echocardiography as well as CT scan or CT angiogra-
phy, the safety, and need for re-connection of the LVAD can
be made.
A simple protocol based on the combination of the time
the LVAD has been disconnected, and the patient’s haemody-
namic condition has been suggested23 and revised here. This
protocol can be easily followed by the EMS:
i Short pump stop (minutes; LVAD still alarming)
• Restart the device immediately.
ii Long pump stop (hours; no alarm sounds) and stable
patient
• Do not restart the pump.
• Transport to the nearest LVAD centre.
iii Short or long pump stop and unstable patient (shock or
non-responsive)
• Restart the pump immediately.
• As in any shock, start vasopressors.
• If there is no overt bleeding, start intravenous (IV) heparin.
Advice for the left ventricular assist device
implanting centres
• Make an ‘identification document’ (ID) bracelet and/or
add a QR code with the relevant medical information.
The bracelet or QR code can include the device manufac-
turer, identification of the implanting centre, phone num-
ber of an LVAD coordinator 24/7, and a short summary
of the patient clinical characteristics.
• Regularly train and re-train the patient, his close caregiver,
and family members.
• Supply a backup controller.
• Have an on call LVAD coordinator 24/7.
• Train the EMS teams, the general practitioner, and other
healthcare professionals working within non-LVAD
implanting hospitals.
• Make a pocket-size emergency card for the patient and lo-
cal medical centres.
Advices for the emergency medical service
instructing a non-trained personnel
When bystanders encounter a collapsed LVAD patient, they
will probably contact the EMS team. The EMS team are ad-
vised to follow the algorithm presented below guiding the by-
stander on how to manage the collapsed LVAD patient until
the EMS team arrives.
The bystander will be asked to verify that this is a case of a
collapsed LVAD patient, and if so, inspect the cables, control-
ler, and batteries. Expose the abdomen and the cable coming
out from the patient’s abdomen confirming this it is indeed
an LVAD patient!
Immediately thereafter, the bystander is instructed to look
for signs of life. Absence of signs of life is determined when
the patient is not breathing at all or in agonal breathing, un-
responsive, and pale.
In the absence of signs of life, the bystander is encouraged
to immediately start CPR as the likelihood of a favourable
outcome improves with the prompt initiation of CPR after
cardiac arrest from any cause.
In summary:
• First verify that there is an LVAD…
• If no sign of life, immediately start CPR and connect an
AED (automated external defibrillator).24
• Look for a bracelet.
• Keep CPR until EMS arrives.
Emergency medical service teams
There have been some recent publications addressing the un-
met need for a structured protocol on the approach and
management of the non-responsive LVAD patient by the
EMS teams. The American scientific statement paper by
Peberdy et al. on CPR in adults and children with MCS24 is
simple and concise, but has not enough data on trouble-
shooting the device, and the issues of reconnecting a discon-
nected LVAD and ventricular arrhythmias in the
LVAD-supported patient have not been thoroughly ad-
dressed. On the other hand, the very detailed manuscript
by Bowels et al. from the UK18 provides comprehensive detail
at the expense of been less user friendly.
Accordingly, with the intention to be a reference protocol
for the EMS at the emergency site, the following protocol is
presented in Figure 3:
• Box 1: Anamnesis. Try to obtain a brief history and infor-
mation on device type and troubleshooting from patient,
caregiver, and/or bystanders. Call the LVAD centre or LVAD
coordinator. Ask for the emergency card.
• Box 2–3 Evaluate patient’s ventilation and perfusion using
breathing pattern, skin colour, temperature, and capillary
Part 1: Introduction and at the non-hospital settings in the community 9
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13588
refill technique. If the equipment is available, check mean
arterial pressure by cuff or Doppler and PETCO2. Values
above 50 and 20 mmHg, respectively, indicate normal
perfusion.
• Box 4: Assess the LVAD function using alarms and ausculta-
tion of the patient’s chest. An LVAD hum indicates that the
LVAD is functioning. Check for integrity and/or disconnec-
tion of the LVAD components: driveline, system controller,
power cables, and batteries. Ask the patient and caregiver
for help with troubleshooting the device alarms.
• If the patient is unstable with nonfunctioning LVAD, follow
Box 8, and perform immediate chest compression.
Figure 3 ACLS algorithm for the left ventricular assist device (LVAD)-supported patient.
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• Box 5 a: Nonfunctioning LVAD in the stable patient. In case
of a short pump stop (if the alarm is still on), try to restart
the device. In case of a long pump stop (no alarms), do not
try to restart the device.
• Box 5 b: Nonfunctioning LVAD in the unstable patient Try
to restart the device, consider administering catechol-
amines and heparin.
• Box 6 a: In the case of a stable patient with functioning
LVAD, consider other causes of altered mental status such
as hypoxaemia, hypoglycaemia, substance abuse, or stroke
and follow to Box 9.
• Box 6 b: After restarting the LVAD, re-evaluate the
LVAD function and perfusion as detailed in Box 4 and
Box 2.
• Box 7: Do not perform external chest compression in the
stable patient.
• Box 8: Perform external chest compression in the persis-
tently unstable patient.
• Box 9: ECG. If the patient is in VF\VT and unstable, defibril-
late. If the patient is stable, do not defibrillate. Organize
immediate transfer to the nearest LVAD centre.
• Box 10: Follow EMS and ACLS protocols. Before transfer-
ring the patient to the nearest LVAD centre, ask the family
for all the LVAD equipment.
• When evaluating LVAD patients in the acute scenario, look
for any identification, ask the patient and\or family for
help, and try to contact the LVAD centre.
• When indicated, start CPR as soon as possible.
• Chest compression is safe in LVAD patients. Avoid using
automated devices.
• Defibrillation is safe in LVAD patients. Avoid defibrillation
of the stable patient.
Arrhythmias in the left ventricular assist
device-supported patient
Arrhythmias are common in LVAD patients, leading to hospi-
talization in 30–40% of the patients within the first 2 years af-
ter the LVAD implantation.7 Some arrhythmias are related to
the underlying heart disease, but others can be induced by
the cardiac surgery (scar around the LVAD inflow cannula)
or by mechanical irritation of the left ventricular wall by the
pump.
Atrial fibrillation (AF) is present prior to LVAD implantation
in 40–60% of patients.25,26 In some patients, even
long-standing AF may convert to sinus rhythm after the LVAD
implant presumably due to improvement in left atrial pres-
sure, but in others AF may develop de novo after the LVAD
implant. In some LVAD-supported patients, AF will become
acutely symptomatic if the RV function is marginal, and in
others, it may lead to poor exercise capacity. Anticoagulation
is rarely an issue for most of the patients receive vitamin K
antagonists as part of their regular LVAD management. Treat-
ment of AF follows the principles applied in non-LVAD-sup-
ported patients,26 but ablation is only rarely considered.
The main determinant of the aggressiveness of the therapeu-
tic strategy is the patient symptoms. In most patients, how-
ever, an attempt to obtain sinus rhythm should be made.
Many patients have been treated with amiodarone prior to
LVAD implant or in the postoperative phase, so ruling out thy-
rotoxicosis is important in LVAD patients presenting with de
novo AF.
Ventricular tachycardia or fibrillation (VT/VF) are also very
commonly reported in up to 20–50% of LVAD recipients.15
The main predisposing factor for VT/VF post-LVAD implanta-
tion is ventricular arrhythmias prior to the implant.27 VT/VF
may arise because of the underlying heart disease, from scar
tissue related to the LVAD operation or due to mechanical ir-
ritation of LV inflow cannula, especially if excessive LV
unloading is present (‘suction’ events).
Sustained VT or even VF does not necessarily lead to acute
haemodynamic compromise in LVAD patients. In fact, pa-
tients living for weeks with resistant VF have been reported28
during which, the patient may present with only mild symp-
toms such as shortness of breath, weakness, and
lightheadedness or even be completely asymptomatic. Dur-
ing sustained VT or VF, although the right ventricular function
is hampered, the systemic blood flow can persist if the LV
preload is maintained with the LVAD functioning indepen-
dently of the arrhythmia. The patient in VT/VF is in a
Fontan-like circulatory situation; thus, maintaining adequate
systemic circulation depends on the balance between the re-
sistance in pulmonary circulation (PVR) and the central ve-
nous pressure. Hence, in patients with low PVR and
adequate venous filling, normal cardiac output at rest may
be maintained, resulting in LVAD patients presenting with
VT/VF but with only mildly, or occasionally not at all, symp-
tomatic. In case the LVAD patient has also been implanted
with an ICD, the patient might experience multiple shocks
while being completely awake. Eventually, VT/VF will lead to
right HF and circulatory compromise and thus needs immedi-
ate therapeutic intervention.
The management of LVAD patients with VT/VF depends on
the clinical presentation of the patient, which, in turn, de-
pends on the PVR and central venous pressure. Patients
should be immediately admitted to a cardiology department
specialized in taking care of cardiac arrhythmias.
Telemonitoring and IV access should be ensured. If the pa-
tient has an ICD, and is conscious, a magnet should be placed
over the ICD immediately to prevent painful discharges. If the
patient is haemodynamically unstable but awake, immediate
sedation and cardioversion is indicated as for the non-LVAD
patient. In the haemodynamically stable LVAD patient with
VT/VF, if the event is short, measured in minutes, immediate
cardioversion may prevent thrombus formation in the RV
and/or on the aortic valve. If the event is prolonged,
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thrombus formed in those two locations should be suspected
and the patient immediately transferred to a VAD centre for
further evaluation and management.18 In the VAD centre, af-
ter ruling out thrombus formed in the LV or by the aortic
valve, IV amiodarone (300 mg) and reduction in pump speed
(if possible, echo guided) should be attempted. If the patient
is dehydrated and echocardiography suggests an unfilled LV,
IV fluid should be administered. In patients not responding
to these measures, sedation and cardioversion must be per-
formed. Further treatment includes optimization of
beta-blocker doses, prolonged antiarrhythmic therapy (often
amiodarone), and ablation in refractory cases.29
It is unclear whether LVAD patients in general benefit from
prophylactic ICD implantation. A meta-analysis of data from
the USA did not suggest this, whereas a recent European
multicentre study found a benefit both from having an ICD
prior to MCS and also from receiving an ICD after LVAD
implantation.30,31 All studies are retrospective and should be
interpreted with caution. It is clear, however, that LVAD pa-
tients with activated ICD are at high risk of experiencing shocks
while awake, and even ultra conservative programming of the
device does not prevent this unpleasant adverse event.32
Currently, the shock therapy mode is kept activated in pa-
tients with ICDs implanted prior to LVAD surgery. Implanting
an ICD while on LVAD support is reserved for those with hae-
modynamically significant ventricular arrhythmias occurring
post-LVAD implantation or in individual patients considered
to be at high arrhythmic risk. In LVAD patients experiencing
awake shocks, a discussion with the patient and family mem-
bers regarding the benefits and risks of deactivating the ICD is
indicated.
A significant proportion of LVAD patients have been treated
with a CRT device prior to LVAD implant. It is unclear whether
the LV lead function is to be left on or turned off. Most likely
there is only a minor gain in terms of prognosis from LV pacing
as the patient has already declared him or herself as a
non-responder by requiring an LVAD implant. Furthermore,
one study has suggested that exercise capacity might improve
in CRT treated LVAD patients if the CRT function is turned
off.33 The mechanism behind this finding is unclear. Finally,
turning off the LV lead increases battery life of the device,
which might be of importance in deferring the need for bat-
tery exchange with its inherent increased infection risk, espe-
cially in the DT population. Therefore, attempt turning off the
LV lead after LVAD, and if no symptoms occur, keep it off.
• Atrial fibrillation may present as right ventricular failure. In
such cases, perform cardioversion.
• Stable LVAD patients presenting with VF\VT must be im-
mediately transferred to a hospital with a cardiology cen-
tre where appropriate method to cardiovert the patient
can be applied.
• In patients with cardiac re-synchronization therapy with a
defibrillator and LVAD, attempt turning the LV lead off
for longer battery life and possible improvement of RV
function.
Considerations for referral (urgent/
non-urgent) to advanced heart failure
centre
Optimal management of patients with LVAD requires a multi-
disciplinary and specialized approach, involving a team that
includes medical technicians, nurses, cardiologists, and sur-
geons. However, because a full range of such expertise can-
not be developed in all cardiology units, a shared care
model based on communication, cooperation, and clear
shared responsibilities in patients care between peripheral
cardiology units and the advanced HF referral centre is advis-
able, within a hub and spoke network model.34–36 The key of
such an approach is to design education and shared responsi-
bility models based on the level of care that each centre of
the network can provide. In this context, peripheral centres
with outpatient and/or inpatient LVAD specific care
programmes may guarantee patient outcomes comparable
to tertiary LVAD hubs.36 Thus, the need and level of referral
depends on whether a shared care network between the ter-
tiary and peripheral centres is in place.
Within this framework, the complications that may occur
in an LVAD patient are to be classified based on the level of
urgency and the corresponding level of expertise in LVAD
management required, although in most cases communica-
tion with the tertiary advanced LVAD hub is advisable. Level
of expertise may be framed on the basis of the recent paper
from Yin et al.36 Centres with no LVAD experience and no
dedicated teams should communicate for any kind of compli-
cation with the LVAD centre, while centres with trained per-
sonnel for at least outpatient management may manage
non-urgent interventions, and centres with dedicated and
trained team for inpatient management could deal also with
electively urgent clinical scenarios.
In Table 2, we outline several scenarios: regardless of
the underlying cause, the urgency of the intervention is re-
lated to clinical presentation in the context of LVAD pa-
tient. For example, low flow alarms may be benign when
related to hypovolaemia and thus may be self-resolving or
managed with fluid intake (a condition that can be re-
motely managed by a VAD coordinator), or, if recurrent
and associated with significant symptoms such as dizziness
or even loss of consciousness, may also be related to life
threatening complications such as outflow obstruction or
twisting needing urgent surgical referral to a highly experi-
enced LVAD centre.
Management of extracardiac conditions require knowledge
as well of basic LVAD functioning principles and interpretation
of clinical scenarios. For example, gastrointestinal bleeding is a
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frequent complication in LVAD patients, which requires with-
holding of anticoagulation, but also careful monitoring of
pump parameters, in particular energy consumption, to detect
promptly indirect signs of possible LVAD thrombosis.37 Simi-
larly, management of extra cardiac surgery requires appropri-
ate cooperation with trained personnel to monitor and
manage volume, BP, and coagulation, to avoid LVAD complica-
tions and malfunction in the operative and post-operative
phase. It is important to underline that LVAD does not repre-
sent a contraindication for even major non-cardiac surgery,
which can be appropriately managed by multidisciplinary ap-
proach and training.38 The level of training in the peripheral fa-
cility dictates the need for referral to the LVAD centre.
Immediately life threatening includes condition for which
immediate interventions are needed and high level of exper-
tise is needed. Early transfer of the patient to advanced HF
centre with LVAD expertise and cardiac surgery is advisable.
Electively urgent indicates conditions needing urgent inter-
vention but which may be initially managed, and in some
cases even resolved in the peripheral centre with personnel
trained for LVAD management and in-hospital facilities in-
cluding intensive care units with staff familiar with LVAD, able
to perform LVAD-specific echocardiography, and able to un-
derstand LVAD parameters and waveforms. These patients
do not necessarily need to be transferred to the advanced
HF hub centre. Delayed/planned indicate conditions that re-
quire attention but that may be managed in the context of
outpatient department or in the context of planned
in-patient interventions. Basic training for LVAD management
is needed as well, although in-patient facilities may not be re-
quired, and the patient can be managed in the peripheral
hospital, with advanced HF centre remote supervision. When
any of these conditions is detected by a centre with no exper-
tise or training in LVAD management, guidance of the local
LVAD hub should be sought.
Components of the LVAD system:
• Inflow cannula—stationed inside the left ventricle con-
nects the LV cavity to the pump directs blood into the
pump
• Pump—the body of the LVAD, located at the apex of the
left ventricle and houses the impeller (magnetically levi-
tated frictionless rotor), connected to the ascending aorta
via the outflow graft
• Outflow graft—flexible conduit that directs blood from the
pump to the ascending aorta
• Driveline—the pump is connected by the DL, a cable sub-
cutaneously tunnelled from the pump exiting the body at
Table 2 Different clinical scenarios, urgency and level of expertise required
Level of urgency requiring
intervention Cardiac/LVAD-related conditions
Extracardiac/non-LVAD-
related conditions Level of expertise
Immediately life threatening • Pump failure
• Pump thrombosis (of high
watt alarm)
• Recurrent or prolonged






• Emergent non cardiac
surgery (i.e. bowel
perforation)
High level LVAD expertise
Electively urgent • VT/VF
• Low-flow alarms
• Self-resolving syncope







• Non-LAD related infections
(i.e. pneumonia)
• Urgent non cardiac surgery
(i.e. cholecystitis, bowel
obstruction)
• Elective non cardiac surgery
Dedicate inpatient
LVAD care
Delayed/planned • Driveline infection:
superficial
• Clinical signs of right heart
failure with no or minor symptoms
• Severe aortic regurgitation
with no or minor symptoms
• Isolated hypotension or
hypertension
• Elective minor non cardiac
surgery (i.e. cataract etc.)






COPD, chronic obstructive pulmonary disease; LVAD, left ventricular assist device; VAD, ventricular assist device; VF, ventricular fibrillation;
VT, ventricular tachycardia.
aThis facility must have a stroke unit.
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the lower abdominal wall, to the external controller and
the energy supply. The cable contains double set of wires
that provide power and operating details to the pump
from the controller
• External controller—the controller is the system’s com-
puter. It monitors pump function (flow, speed, and power),
controls pump speed and power supply, records pump
data and alarms; displays battery life and function. The
controller is connected to the driveline and to the power
sources (the batteries or external power supply like the
wall socket)
• Batteries—two lithium batteries.
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